EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

March 20 (Reuters) - EyePoint ‌filed a lawsuit ​on ​Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and ‌its lead experimental eye drug.

The complaint was filed in ⁠Middlesex County Superior Court for the Commonwealth of Massachusetts.

The two ‌companies are rivals in the ‌race to develop longer-lasting treatments for serious retinal diseases, including wet age-related macular degeneration, or wet AMD, ​a leading cause of vision loss in older adults.

EyePoint said Ocular Therapeutix made statements that misrepresented ⁠the company and the clinical results of the drug, Duravyu.

The company is accusing ​Ocular Therapeutix of defamation, commercial disparagement, and violations of Massachusetts consumer protection law. It also ​accused Ocular Therapeutix of interfering ‌with its business relationships.

EyePoint is asking the court to order Ocular Therapeutix to stop ⁠making the statements, issue a public retraction, and pay monetary damages and legal fees.

"We're confident in our statements and look ⁠forward to responding in the course of the legal process," an ​Ocular spokesperson said.

Duravyu is currently being evaluated in late-stage studies for wet age-related macular degeneration and diabetic macular edema, with data ‌for wet AMD expected beginning in mid-2026.

Ocular's leading eye drug, Axpaxli, meanwhile, met the ‌main goal of a key late-stage trial last month, ⁠helping patients with wet ‌AMD maintain their vision ​compared to Regeneron's approved blockbuster drug Eylea.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan ‌Barona)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• White House denies report US is considering a diesel export ban
• Europeans warn of rising Russian sabotage but see no imminent NATO attack
• Israeli bulldozers smash Palestinian olive trees ahead of annual harvest